Intra-articular injection of compound betamethasone and hyaluronic acid for the treatment of moderate-severe knee osteoarthritis:a randomized controlled trial.
10.12200/j.issn.1003-0034.2021.05.006
- Author:
Shan-Zheng WANG
1
;
Yu-Dong GUO
1
;
Xue-Jun ZHANG
1
;
Chen WANG
1
Author Information
1. Department of Orthopaedics, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, Jiangsu, China.
- Publication Type:Randomized Controlled Trial
- Keywords:
Compound betamethasone;
Hyaluronic acid;
Knee joint;
Osteoarthritis
- MeSH:
Betamethasone;
Child;
Child, Preschool;
Female;
Humans;
Hyaluronic Acid;
Injections, Intra-Articular;
Male;
Osteoarthritis, Knee/drug therapy*;
Prospective Studies;
Treatment Outcome
- From:
China Journal of Orthopaedics and Traumatology
2021;34(5):424-428
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare clinical effects of compound betamethasone and compound betamethasone with hyaluronic acid in treating moderate-severe knee osteoarthritis (KOA).
METHODS:A prospective randomized controlled study was conducted in 116 patients with unilateral moderate-severe KOA patients from February 2017 to November 2017 and divided into observation group and control group, 58 patients in each group. In observation group, there were 15 males and 43 females aged from 45 to 80 years old with an average of (66.45±6.31) years old;according to Kellgren-Lawrence(K-L) classification, 42 patients were type Ⅲ and 16 patients were type Ⅳ;the courses of disease ranged from 4 to 8 years with an average of (5.25±2.21) years;the patients were treated by injecting 1 ml compound betamethasone into knee joint. In control group, there were 13 males and 45 females aged from 45 to 80 years old with an average of (64.89±6.41) years old;according to K-L classification, 43 patients were type Ⅲ and 15 patients were type Ⅳ;the courses of disease ranged from 4 to 10 years with an average of (5.41±2.35) years;the patients were treated by knee joint injection of 4 ml hyaluronic acid and 1 ml compound betamethasone. Visual analog scale (VAS), Western Ontario and McMaster University Osteoarthritis Index (WOMAC) were used to evaluate clinical effects before treatment and 1 week, 1, month, 3 and 6 months after treatment.
RESULTS:Totally 55 patients in observation group were followed up for 6 months, and 3 patients were quit at 3 months after treatment for poor efficacy. Totally 56 patients in control group were followed up for 6 months, and 2 patients were withdrew from the follow-up on the first and third month respectively for poor efficacy. There were no statistical difference in VAS and WOMAC between two groups before treatment and different time points after treatment (
CONCLUSION:For patients with moderate-severe KOA, there is no significant difference in therapeutic effect between compound betamethasone injection and compound betamethasone combined with hyaluronic acid injection, and long-term effect of two methods is not good.
